NCI-COG Pediatric MATCH Molecular Analysis for Therapy Choice- A Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes
Randomized Blinded Phase 3 Assessment of Second-or Third Line Chemotherapy with Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients with Advanced Non-Small Cell Lung Cancer with at Least 1 Large Lung Lesion,DUBLIN-3
Phase II Single Blind Randomized Trial Comparing Morbidity and Mortality of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy CRS-HIPEC using Mitomycin-C versus Melphalan for Colorectal Peritoneal Carcinomatosis ? A KUCC ? Funded Pilot Trial
A First-in-Human FIH, Phase 1, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Orally Administered GLB-001 in Patients with Refractory or Relapsed Acute Myeloid Leukemia R/R AML or Refractory or Relapsed Higher-risk Myelodysplastic Syndromes R/R HR-MDS
A Phase II Single Arm Proof Of Concept, Safety, Efficacy, Multicenter Study Of Brentuximab Vedotin As Consolidation Therapy After Autologous Stem Cell Transplant In CD 30 Expressing Peripheral T Cell Lymphomas BRENTICON-T
Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
A Randomized, Multicenter, Double-Blind Phase III Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib For the Treatment of Patients with ER +, HER2 - Breast Cancer Who Have Not Received Any Prior Systemic Anti-Cancer Treatment for Advanced Disease
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer NIAGARA